Phase 3 N=484 Denosumab China Phase III Study
Osteoporosis, Postmenopausal
Primary: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12 — 5.22; 0.79 Percentage change — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=40 ADAM-Afatinib Diarrhea Assessment and Management
Carcinoma, Non-Small-Cell Lung
Primary: Occurence of CTCAE Grade >= 2 Diarrhea — 72.20; 31.80 Percentage of participants
Phase 3 N=499 A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48 — 82; 71 Percentage of participants — p=0.005
Phase 3 N=63 A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Cytomegalovirus Infections
Primary: Mean Area Under the Concentration-Time Curve From 0 to 24 Hours of Valganciclovir — 65.2; 55; 50; 69.4 mcg*hr/mL
Phase 3 N=120 Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
Anal Cancer · Neoplasm of Uncertain Malignant Potential · Nonneoplastic Condition
Primary: Complete Response Through 1 Year — 38; 16 participants
Phase 3 N=3,556 Preventing Sexual Transmission of HIV With Anti-HIV Drugs
HIV Infections
Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001
Phase 3 N=796 Efficacy and Safety of GTR in Comparison to Copaxone®
Multiple Sclerosis
Primary: The Number of T1-Gadolinium Enhancing Lesions During Months 7-9 — 0.42; 0.38; 0.82; 0.45 Number of lesions
Phase 3 N=81 HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment — 39.5; 34.9 percentage of participants — p=0.6746
Phase 3 N=55 Journeys to Wellness: A Transplant Candidate Study
End-stage Renal Disease
Primary: State-Trait Anxiety Inventory — 42.1; 37.8; 40.6; 34.8 units on a scale
Phase 3 N=3,876 Insulin Resistance Intervention After Stroke Trial
Stroke · Myocardial Infarction · Diabetes
Primary: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction — 175; 228 participants — p=.0067
Phase 3 N=677 BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
Post-Menopausal Osteoporosis
Primary: Percentage of Participants Current Daily or Weekly Bisphosphonate Users in Part A Who Answer 'Yes' to Any of the Questions in the Candidate Identification Questionnaire…
Phase 3 N=221 Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure
Heart Failure
Primary: Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) — 33; 36 participants
Phase 3 N=478 A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Schizophrenia
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 51; 190 participants
Phase 3 N=417 A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
Psoriasis, Arthritic
Primary: Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic…
Phase 3 N=122 A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
Arthritis, Rheumatoid
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 56; 58 participants